Hospira 3Q Revenues: $838 million (+30%) 3Q Earnings: $59 million (+6%) YTD Revenues: $2.5 billion (+26%) YTD Earnings: $61 million (-68%) Comments: Integration of Mayne Pharma helped drive revenue growth, while restructuring costs drove down earnings. Injectable Pharmaceutical Contract Manufacturing revenues were down 12% to $33.5 million in 3Q and down 20% to $111.6 million YTD....